R. Rondena

Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.

D. Amadori, V. Lorusso, G. Cartenì, 2006, The oncologist.

5(4H)-Oxazolones. Part VIII.1 An Efficient Synthesis of Δ1-Pyrroline-2-carboxylic Acid derivatives through Michael and Wittig condensation

F. Clerici, D. Pocar, R. Rondena, 1995 .

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

D. Amadori, M. Aglietta, D. Santini, 2013, The Lancet. Oncology.

Parsimonious modeling of vegetation dynamics for ecohydrologic studies of water‐limited ecosystems

Marco Mancini, John D. Albertson, Nicola Montaldo, 2005 .

ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment.

D. Amadori, M. Aglietta, D. Santini, 2012 .

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

D. Amadori, M. Aglietta, D. Santini, 2013, The Lancet. Oncology.